Benefits of Total Intravenous Anesthesia Compared With Inhaled Anesthesia in Cardiovascular Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03233815|
Recruitment Status : Recruiting
First Posted : July 31, 2017
Last Update Posted : November 17, 2017
|Condition or disease||Intervention/treatment|
|Cardiovascular Surgical Procedure||Drug: Propofol Drug: Sevoflurane|
|Study Type :||Observational|
|Estimated Enrollment :||40 participants|
|Official Title:||Benefits of Total Intravenous Anesthesia Compared With Inhaled Anesthesia in Cardiovascular Surgery|
|Actual Study Start Date :||November 13, 2017|
|Estimated Primary Completion Date :||July 2019|
|Estimated Study Completion Date :||July 2019|
Inhaled anesthesia (Sevoflurane)
Patients undergoing cardiovascular surgery with inhaled anesthesia with sevoflurane.
Inhaled anesthesia with sevoflurane. Dose: 1-2.5 Minimum Alveolar Concentration(MAC)
Other Name: Sevorane
Total Intravenous Anesthesia (Propofol)
Patients undergoing cardiovascular surgery with total intravenous anesthesia with propofol.
Propofol anesthesia Dose: 4-6mg/kg/h
Other Name: Diprivan
- IL-6 [ Time Frame: The difference between IL-6 at the begging of surgery and 20 minutes after the end of the cardiopulmonary bypass ]IL-6 will be compared between the groups.
- TNFα [ Time Frame: The difference between TNFα at the begging of surgery and 20 minutes after the end of the cardiopulmonary bypass ]TNFα will be compared between the groups
- Cortisol [ Time Frame: The difference between cortisol at the begging of surgery and 20 minutes after the end of the cardiopulmonary bypass ]Cortisol will be compared between the groups
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03233815
|Contact: Ana Gallardo, PhD||5556276900 ext firstname.lastname@example.org|
|Hospital de cardiología||Recruiting|
|Ciudad de mexico, Cdmx, Mexico, 06720|
|Contact: Ana Gabriela Gall, PhD|
|Principal Investigator:||Ana Gallardo, PhD||Instituto Mexicano del Seguroa Social|